Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM)
Conditions
Interventions
Abatacept subcutaneous
Placebo
Locations
79
United States
Local Institution - 0015
Phoenix, Arizona, United States
Local Institution - 0075
Beverly Hills, California, United States
Local Institution - 0012
Orange, California, United States
Local Institution - 0057
Washington D.C., District of Columbia, United States
Local Institution - 0018
Fort Lauderdale, Florida, United States
Local Institution - 0013
Miami, Florida, United States
Start Date
May 4, 2017
Primary Completion Date
July 27, 2020
Completion Date
August 2, 2022
Last Updated
October 30, 2023
NCT04402086
NCT07160205
NCT07374107
NCT07089121
NCT06371417
NCT02945345
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions